Abstract

Background

Migraine is a common brain disorder but reliable diagnostic biomarkers in blood are still lacking. Our aim was to identify, using proton nuclear magnetic resonance (1H-NMR) spectroscopy, metabolites in serum that are associated with lifetime and active migraine by comparing metabolic profiles of patients and controls.

Methods

Fasting serum samples from 313 migraine patients and 1512 controls from the Erasmus Rucphen Family (ERF) study were available for 1H-NMR spectroscopy. Data was analysed using elastic net regression analysis.

Results

A total of 100 signals representing 49 different metabolites were detected in 289 cases (of which 150 active migraine patients) and 1360 controls. We were able to identify profiles consisting of 6 metabolites predictive for lifetime migraine status and 22 metabolites predictive for active migraine status. We estimated with subsequent regression models that after correction for age, sex, BMI and smoking, the association with the metabolite profile in active migraine remained. Several of the metabolites in this profile are involved in lipid, glucose and amino acid metabolism.

Conclusion

This study indicates that metabolic profiles, based on serum concentrations of several metabolites, including lipids, amino acids and metabolites of glucose metabolism, can distinguish active migraine patients from controls.

Details

Title
Metabolic profile changes in serum of migraine patients detected using 1H-NMR spectroscopy
Author
Harder Aster V E 1   VIAFID ORCID Logo  ; Vijfhuizen, Lisanne S 2 ; Henneman, Peter 3 ; Willems van Dijk Ko 4 ; van Duijn Cornelia M 5 ; Terwindt, Gisela M 6 ; van den Maagdenberg Arn M J M 1 

1  Leiden University Medical Centre, Departments of Human Genetics, Leiden, The Netherlands (GRID:grid.10419.3d) (ISNI:0000000089452978); Leiden University Medical Centre, Department of Neurology, Leiden, The Netherlands (GRID:grid.10419.3d) (ISNI:0000000089452978) 
2  Leiden University Medical Centre, Departments of Human Genetics, Leiden, The Netherlands (GRID:grid.10419.3d) (ISNI:0000000089452978) 
3  Amsterdam University Medical Centre, Department of Clinical Genetics, Genome Diagnostic laboratory, Amsterdam Reproduction & Development research institute, Amsterdam, The Netherlands (GRID:grid.509540.d) (ISNI:0000 0004 6880 3010) 
4  Leiden University Medical Centre, Departments of Human Genetics, Leiden, The Netherlands (GRID:grid.10419.3d) (ISNI:0000000089452978); Leiden University Medical Centre, Einthoven Laboratory for Experimental Vascular Medicine, Leiden, The Netherlands (GRID:grid.10419.3d) (ISNI:0000000089452978); Leiden University Medical Centre, Department of Internal Medicine, Division of Endocrinology, Leiden, The Netherlands (GRID:grid.10419.3d) (ISNI:0000000089452978) 
5  Erasmus Medical Centre, Department of Epidemiology, Rotterdam, The Netherlands (GRID:grid.5645.2) (ISNI:000000040459992X); Oxford University, Nuffield Department of Population Health, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948) 
6  Leiden University Medical Centre, Department of Neurology, Leiden, The Netherlands (GRID:grid.10419.3d) (ISNI:0000000089452978) 
Publication year
2021
Publication date
Dec 2021
Publisher
Springer Nature B.V.
ISSN
11292369
e-ISSN
11292377
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1186/s10194-021-01357-w
ProQuest document ID
2601729534
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.